Introduction {#Sec1}
============

Blood vessels originate from endothelial precursors (angioblasts), which give rise to a primitive vascular labyrinth of small capillaries, a process known as vasculogenesis \[[@CR1]\]. During subsequent angiogenesis, the vascular plexus progressively expands through vessel sprouting \[[@CR1]\]. The sprouting process is based on endothelial cell (EC) migration toward chemotactic and angiogenic stimuli, proliferation and tube formation. Afterward, a highly organized network of larger vessels ramifying into smaller ones, emerges. A functional circulatory system is essential to guarantee oxygen and nutrients delivery to distant organs \[[@CR2]\]. Consistently, angiogenesis is crucial for organ growth in the developing embryo and repair of wounded tissues in the adult \[[@CR1]\]. Many molecular players are involved in the formation and remodeling of blood vessels, including growth factors, integrins, chemokines, junctional molecules and oxygen sensors. Interestingly, metabolic demands are also thought to modulate angiogenesis \[[@CR3]\]. Intrinsic, as well as extrinsic factors involved in the regulation of angiogenesis, show a dual role, by both stimulating vessel growth and inhibiting EC death. Indeed, excessive cell death might interfere with angiogenesis and actively lead to vessel regression \[[@CR4]\]. Stimuli that cause endothelial injury or death include environmental stressors such as oxidative stress and nutrient deprivation, endoplasmic reticulum (ER) stress and metabolic stress \[[@CR5], [@CR6]\]. Here, we provide evidence that heme homeostasis in ECs controls the angiogenic process. In particular, we show that the expression of the heme exporter Feline leukemia virus subgroup C receptor 1a (FLVCR1a) on ECs is essential for proper angiogenesis. FLVCR1 is a widely conserved heme export protein, which exists as two isoforms, FLVCR1a and FLVCR1b, located at the plasma and mitochondrial membrane, respectively \[[@CR7]\]. Heme, a complex of iron with protoporphyrin IX, is required for many biological processes, including oxygen transport, cell respiration and drug metabolism but has also cytotoxic properties as a pro-oxidant molecule \[[@CR8]\]. Therefore, intracellular heme levels are strictly regulated through the biosynthesis, the incorporation in hemoproteins, the catabolism and the export \[[@CR9]\]. Heme export through FLVCR1a has proved fundamental in preventing intracellular heme overload and heme-induced oxidative stress in many cellular systems, including HeLa, Caco2, primary hepatocytes and macrophages \[[@CR7], [@CR10]--[@CR12]\]. Furthermore, FLVCR1a loss in mice causes embryonic lethality \[[@CR7]\], whereas intestinal-specific deletion impairs normal proliferation in enterocytes and FLVCR1a depletion in a mouse model of ulcerative colitis is associated with reduced animal survival \[[@CR12]\]. Consistently, *FLVCR1a* silencing affects cell viability in K562 cells \[[@CR13]\] and induces programmed cell death (PCD) in neuroblastoma cells \[[@CR14]\]. These data suggest that FLVCR1a deficiency may increase the susceptibility to PCD. Here, we show that FLVCR1a loss in ECs leads to an expansion of the intracellular heme pool and promotes cell death by paraptosis, a specific type of PCD. Paraptosis of *Flvcr1*a null ECs in mouse embryo prevents the formation of a functional microvascular network, thus leading to extensive hemorrhages and embryonic lethality.

Results {#Sec2}
=======

Silencing of FLVCR1a in human ECs results in increased heme levels and reduced viability {#Sec3}
----------------------------------------------------------------------------------------

FLVCR1a has been reported to act as a heme exporter in hepatocytes \[[@CR10]\], enterocytes \[[@CR12]\] and erythroid cells \[[@CR13]\]. Here, we tested whether FLVCR1a exerts a similar function in ECs. To address this point, we downmodulated *FLVCR1a* in two different types of human primary ECs: the human microvascular ECs (HMECs) and the human umbilical vein ECs (HUVECs), which derive from micro- and macro-vasculature, respectively. To downmodulate *FLVCR1a*, ECs have been infected with a lentiviral vector carrying the specific short hairpin RNA (shRNA) for *FLVCR1a* or a "scramble" shRNA as control. *FLVCR1a* mRNA levels were significantly reduced to about 40% in both HMECs (Fig. [1a](#Fig1){ref-type="fig"}) and HUVECs (Fig. [1c](#Fig1){ref-type="fig"}). Conversely, the *FLVCR1b* isoform was not affected (Figs. [1b, d](#Fig1){ref-type="fig"}). To study the effects of FLVCR1a loss on heme metabolism, the expression of heme-regulated genes was assessed in silenced human primary ECs. Interestingly, we found reduced levels of the δ-aminolevulinic acid synthase-1 (*ALAS-1)*, the first and rate-limiting enzyme involved in heme biosynthetic pathway, in *FLVCR1a*-downregulated HMECs and HUVECs compared with scramble cells (Figs. [1e, g](#Fig1){ref-type="fig"}). The expression of heme oxygenase-1 (*HO1*), the enzyme mainly responsible for heme catabolism, was not altered in HMECs and slightly but not significantly increased in HUVECs after *FLVCR1a* silencing (Figs. [1f, h](#Fig1){ref-type="fig"}). These data suggest that the first compensatory response to the lack of heme export in ECs is the decrease of endogenous heme biosynthesis. Next, we directly measured the intracellular heme content in basal HMECs and we found a higher amount of heme after *FLVCR1a* silencing compared with scramble cells (Fig. [1i](#Fig1){ref-type="fig"}). In HUVECs, we did not find any difference in heme levels after *FLVCR1a* silencing (Fig. [1k](#Fig1){ref-type="fig"}). This is likely due to the more efficient downmodulation of *ALAS1* and the slight increase in *HO1* in HUVECs compared with HMECs, which might better compensate for the lack of heme export in this cell line. However, *FLVCR1a*-downregulated HUVECs showed increased intracellular heme levels compared with control cells, upon treatment with the heme precursor δ-Aminolevulinic acid (ALA) (Fig. [1k](#Fig1){ref-type="fig"}). Notably, the increased intracellular heme content was associated to a higher production of reactive oxygen species (ROS) in HMECs under resting conditions and in HUVECs following ALA treatment (Figs. [1j, l](#Fig1){ref-type="fig"}), as previously reported in other cell types undergoing intracellular heme accumulation \[[@CR10], [@CR12], [@CR15]\]. Taken together, these data show that *FLVCR1a*-downregulated ECs accumulate *de novo* synthetized heme, which in turn gives rise to high ROS production. To investigate the effects of heme overload on ECs viability, we performed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry analysis after Annexin V staining. Interestingly, *FLVCR1a*-silenced cells were less viable (Figs. [1m, o](#Fig1){ref-type="fig"}) and a higher percentage of Annexin V-positive cells was found in *FLVCR1a*-downregulated HMECs and HUVECs compared with scramble cells (Figs. [1n, p](#Fig1){ref-type="fig"}).Fig. 1Lack of FLVCR1a results in increased heme levels and reduced viability in endothelial cells**a-h** qRT-PCR analysis of *FLVCR1a* **a**,**c**, *FLVCR1b* **b**, **d**, *ALAS1* **e**, **g** and *HO1* **f**,**h** in HMECs **a**, **b**, **e**, **f** or HUVECs **c**,**d**, **g**,**h** in which the expression of *FLVCR1a* was downregulated using a specific shRNA 1**a**. Transcript abundance, normalized to 18s mRNA expression, is expressed as a fold increase over a calibrator sample. Data represent mean ± SEM, *n* = 5; \*p \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001. **i**, **k** Heme content in HMECs **i** or HUVECs **k** in which the expression of *FLVCR1a* was downregulated using a specific shRNA. Intracellular heme levels in HUVECs cultured in basal condition or treated with δ-aminolevulinic acid (ALA) 5 mM for 2--4 h, are shown in **k**. Values are expressed as pmol heme/mg protein. Data represent mean ± SEM, *n* = 10; \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001. **j**, **l** ROS amount measured by detection of H2DCFDA fluorescence in HMECs **j** or HUVECs **l** with or without FLVCR1a in basal condition or after treatment with ALA 5 mM for 15 h. Values are expressed as FIU/mg protein. Data represent mean ± SEM, *n* = 4; \**p* \< 0.05. **m**, **o** Cell viability assessed through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay of HMECs **m** or HUVECs **o** in which the expression of *FLVCR1a* was downregulated using a specific shRNA. Values are expressed as percentage increase at 24, 48 h compared with T0 (time zero). Data represent mean ± SEM, *n* = 8 (HMECs),*n* = 3 (HUVECs); \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001. **n**, **p** Flow cytometry assay performed on HMECs **n** or HUVECs **p** with or without FLVCR1a, after incubation with Annexin V-FITC antibody. Values are expressed as percentage of Annexin V high/PI low cells. Data represent mean ± SEM, *n* = 3; \**p* \< 0.05. ALAS1 δ-aminolevulinate synthase-1; HO1 heme oxygenase-1; RQ relative quantification; qRT-PCR quantitative real-time PCR; ROS reactive oxygen species; shRNA short hairpin RNA; ALA δ-aminolevulinic acid; PI propidium iodide

These data demonstrate that ECs are highly sensitive to the absence of the cell surface heme exporter, as the loss of FLVCR1a leads to intracellular heme accumulation, oxidative stress and reduced cell viability.

Endothelial deletion of Flvcr1a leads to embryonic lethality and extensive hemorrhages in vivo {#Sec4}
----------------------------------------------------------------------------------------------

To study the role of FLVCR1a in ECs in vivo, we generated an endothelial-specific knockout (eKO) mouse model for FLVCR1a (Figs. [2](#Fig2){ref-type="fig"}a-d). To this end, we crossed *FLVCR1a* floxed mice with Tie2-Cre mice, expressing the Cre recombinase under the control of the Tie2 promoter, which is mainly active in the endothelial and erythroid compartments. Importantly, we did not recover any viable *Flvcr1a* eKO within the offspring (Table [1](#Tab1){ref-type="table"}), thus indicating that disruption of *Flvcr1a* gene in ECs results in embryonic lethality. *Flvcr1a* eKO embryos were found at the expected Mendelian ratio from embryonic stage E11.5 to embryonic stage E14.5 (Table [1](#Tab1){ref-type="table"}). At 11.5 days of embryonic development, *Flvcr1a* eKO embryos appeared normal (Fig. [2e](#Fig2){ref-type="fig"}). Starting from E12.5, massive intraembryonic bleeding was visible in the distal regions of the body, particularly the developing limbs or the tail, and in the yolk sac (Figs. [2](#Fig2){ref-type="fig"}f-h). In *Flvcr1a* eKO limbs, the hemorrhages were often associated to edema and skeletal malformation, as suggested by impaired digits formation (Figs. [2g, h](#Fig2){ref-type="fig"}). At E14.5 *Flvcr1a* eKO embryos appeared heavily damaged (Fig. [2h](#Fig2){ref-type="fig"}), whereas at E16.5 viable *Flvcr1a* eKO embryos were no longer found (Fig. [2i](#Fig2){ref-type="fig"}). This phenotype showed complete penetrance indicating that FLVCR1a loss in ECs leads to severe bleeding *in vivo* and embryonic death between E14.5 and E15.5. To better investigate the organogenesis and overall morphology in *Flvcr1a* eKO embryos, X-ray computed micro-computed tomography (micro-CT) was performed on E13.5 embryos (Fig. [2j](#Fig2){ref-type="fig"}). The analysis of embryonic internal organs did not reveal the presence of evident malformations in *Flvcr1a* eKO embryos compared with controls, except for the fetal liver that was smaller in *Flvcr1a* eKO embryos due to the Cre activity in erythroid precursors \[[@CR13]\] (Supplementary Figure [S1](#MOESM1){ref-type="media"}). Consistently, the histological analysis performed on E12.5 *Flvcr1a* eKO showed no altered cell morphology in major organs (Fig. [2k](#Fig2){ref-type="fig"}).Fig. 2Endothelial loss of FLVCR1a results in embryonic lethality**a** Schematic representation of the knockout strategy in mice. Briefly, we named "floxed allele" the allele in which the first exon of *Flvcr1* gene was flanked by loxP sites, recognizable by the Cre transgene. The excision of exon 1 results in a null allele preventing the production of FLVCR1a protein. **b** Representative PCR products from yolk sac DNA analysis of E13.5 embryos. Specific primers allowed distinguishing the wt (242 bp), floxed (280 bp) and null allele (320 bp) of *Flvcr1a*. **c**, **d** qRT-PCR analysis showing *Flvcr1a* mRNA levels in E13.5 whole embryo **c** and yolk sac **d**. Data represent mean ± SEM; \**p* \< 0.05, \*\**p *\< 0.01. **e** Phenotype of E11.5 control and *Flvcr1a* eKO embryos. **f** E13.5 embryos enfolded in their yolk sacs. At E13.5, major yolk sac vessels in Tie2-Cre conditional mutant embryos are clearly visible and hemorrhagic spots were often observed within the yolk sac (white arrows). **g** Representative picture of E13.5 control and *Flvcr1a* eKO embryos with undeveloped limbs and intraembryonic hemorrhages (white arrows). **h**, **i** Representative pictures of E14.5 **h** and E16.5 **i** embryos. At E16.5 endothelial *Flvcr1a* knockout, embryos begin to be re-absorbed by the endometrium. White arrows indicate hemorrhages. **j** X-ray computer micro-tomography analysis on E13.5 embryos showing the internal organ morphology. **k** Sagittal sections from E13.5 embryos stained with hematoxylin and eosin to look at the cellular morphology in tissues. RQ relative quantification; eKO, *Flvcr1a* endothelial knockout; E embryonic stageTable 1Loss of FLVCR1a in endothelial cells leads to embryonic deathEmbryonic stage*N*Flvcr1a^flox/+^Flvcr1a^flox/+^ Tie2CreFlvcr1a^flox/flox^Flvcr1a^flox/flox^ Tie2cre11.5--12.55710 (17.5%)14 (24.5%)13 (22.8%)20 (35%)13.519032 (16.8%)56 (29.5%)56 (29.5%)46 (24,2%)14.5288 (28.6%)7 (25%)6 (21.4%)7 (25%)Newborns4613 (28.2%)17 (36.9%)16 (34.7%)0 (0%)

Collectively, our results indicate that FLVCR1a loss in ECs impairs vascular development by leading to severe hemorrhages and late intrauterine fetal death.

Loss of FLVCR1a in ECs disrupts microvessel architecture {#Sec5}
--------------------------------------------------------

To further investigate the cause of hemorrhages, we analyzed the vasculature of *Flvcr1a* eKO embryos at E11.5 when hemorrhages were not detectable, by performing whole-mount staining for PECAM-1 (CD31), a pan-EC marker. At the level of developing limbs, which are the sites where hemorrhages would appear earlier, the structure of the vascular network was severely impaired in E11.5 *Flvcr1a* eKO embryos compared with controls (Fig. [3a](#Fig3){ref-type="fig"}). In control embryos, a well-defined network of capillaries was properly organized throughout the limb bud. Conversely, in *Flvcr1a* eKO mutants, microvessel architecture was compromised and large areas completely devoid of vessels were observed in both the forelimbs and the hindlimbs (Fig. [3a](#Fig3){ref-type="fig"}). Notably, when we looked at the vascular network in other regions of E11.5 *Flvcr1a* eKO embryo's body, as the yolk sac and the head, vessels appeared generally intact (Supplementary Figure [S2](#MOESM1){ref-type="media"}). As the limbs' capillaries are mainly composed of microvascular cells, we used HMECs to study the ability of *FLVCR1a*-silenced human microvascular cells to generate tubule-like structures *in vitro*. Interestingly, silenced cells showed a reduced ability to form a complex capillary network compared with scramble cells (Fig. [3b](#Fig3){ref-type="fig"}). These results highlight a key role for FLVCR1a in the formation of a properly patterned capillary network, which is essential for the development of a functional circulatory system.Fig. 3*Flvcr1a* endothelial knockout embryos show impaired vascular integrity**a** Whole-mount staining with CD31/Pecam-1 antibody showing the embryonic vasculature in E11.5 embryos. Enlarged pictures of both the forelimb (left) and the hindlimb (right) are reported. **b** Matrigel-based tube formation assay of HMECs in which the expression of *FLVCR1a* was downregulated using a specific shRNA. The histograms of the number of nodes, junctions, segments and isolated segments are shown. The total segments length is also reported. Data represent mean ± SEM, *n* = 19; \**p* \< 0.05. eKO *Flvcr1a* endothelial knockout; scr cells infected with a "scramble" shRNA; 1a, cells infected with a shRNA specific for *FLVCR1a*

Loss of FLVCR1a in ECs causes paraptotic cell death {#Sec6}
---------------------------------------------------

In order to understand why FLVCR1a-deficient ECs fail to form a proper capillary network, we performed electron microscopy analysis on forelimb transverse sections from both *Flvcr1a* eKO and control E11.5 embryos (Fig. [4](#Fig4){ref-type="fig"}). *Flvcr1a* null ECs were characterized by the presence of several intracellular vacuoles of different sizes and shapes (Figs. [4a, b, d, e](#Fig4){ref-type="fig"}). The vacuoles often originated from an enlargement of the ER and mitochondria (Figs. [4c, f](#Fig4){ref-type="fig"}). Intracellular vacuoles can reach extended size, sometimes affecting the entire cytoplasmt (Figs. [4](#Fig4){ref-type="fig"}g-i). Interestingly, cytoplasmic vacuolation is the main feature of paraptosis, a specific type of PCD characterized by ER and mitochondria swelling and lack of apoptotic or autophagic morphology \[[@CR16]\]. Consistently, the defining morphological hallmarks of apoptosis such as chromatin condensation, nuclear fragmentation and apoptotic body formation, were not observed in *Flvcr1a* null ECs (Fig. [5a](#Fig5){ref-type="fig"}). Moreover, the intracellular vacuoles observed in ECs without FLVCR1a did not contain fragments of cellular organelles and in most cases were defined by single membranes, leading us to exclude an autophagic mechanism (Fig. [5b](#Fig5){ref-type="fig"}). To confirm that *Flvcr1a* null ECs undergo paraptosis, we analyzed CD31+ cells isolated from *Flvcr1a* eKO embryos (Figs. [5](#Fig5){ref-type="fig"}c-e, Supplementary Figure [S3](#MOESM1){ref-type="media"}) for biochemical markers of this type of cell death, that is, translocation of phosphatidylserine to the cell surface, no caspase activation and lack of expression of autophagic markers \[[@CR16]--[@CR18]\]. As shown in Figs. [5f, g](#Fig5){ref-type="fig"}, we found a higher percentage of Annexin V-positive cells in *Flvcr1a* null ECs at both E11.5 and E14.5. Moreover, *Flvcr1a* null ECs did not express activated caspase-3 (Fig. [5h](#Fig5){ref-type="fig"}) and did not show abnormal expression of the autophagic marker LC3B (Figs. [5i, j](#Fig5){ref-type="fig"}). Importantly, these morphological and biochemical features were associated to heme overload (Fig. [5k](#Fig5){ref-type="fig"}) and normal expression of *HO1* (Fig. [5l](#Fig5){ref-type="fig"}) suggesting that developing ECs are fully dependent on heme export for detoxifying heme excess. Taken together, these data demonstrate that loss of FLVCR1a in ECs leads to heme accumulation which triggers paraptotic cell death.Fig. 4Endothelial cells without FLVCR1a show paraptotic cell death morphological features**a-i** Electron microscopy analysis performed on transverse section from E11.5 embryonic forelimbs. Two capillaries from a control **a**, **b** and an eKO **d**, **e** embryo are shown. *Flvcr1a* null ECs display extensive cytoplasmic vacuolation **d**, **e** and an altered swollen morphology of ER and mitochondria **f** compared with controls **c**. In **g**, a small limb capillary made of two *Flvcr1a* null ECs is shown. The presence of huge intracellular vacuoles and heavily damaged mitochondria without cristae (black arrowheads) is clearly visible in the enlargements **h**, **i**. eKO *Flvcr1a* endothelial knockout; BC blood cell; EC endothelial cell; IEJ inter endothelial junction; V vacuole; M mitochondrion; N nucleus; ER endoplasmic reticulumFig. 5FLVCR1a null endothelial cells accumulate heme and show reduced viability *in vivo***a** Electron micrographs showing the nuclear morphology of a control (left) and an *Flvcr1a* null EC (right). The main apoptotic features as chromatin condensation and nuclear fragmentation are not observed in *Flvcr1a* null ECs. **b** Electron micrographs showing the single-membrane vacuoles (black arrowheads) in *Flvcr1a* null ECs from E11.5 forelimb transverse sections. **c** Optical imaging on CD31+ cells isolated from E13.5 control and eKO embryos. Black arrows indicate intracellular vacuoles. **d**, **e** qRT-PCR analysis of *Flvcr1a* **d** and *Flvcr1b* **e** in CD31-positive and -negative cell fractions from E13.5 embryos. Values represent mean ± SEM;*n* = 5; \*\*\**p* \< 0.001. **f**, **g** Flow cytometer analysis of CD31+ cells from E11.5 **f** and E14.5 **g** embryos after staining with Annexin V. The percentage of Annexin V/CD31 double-positive cells is reported. \**p* \< 0.05, \*\**p* \< 0.01. **h** Western blot analysis of full-length (35 kDa) and cleaved (17--19 kDa) caspase-3. The active form of caspase-3 was not detected in CD31+ cells from E13.5 eKO embryos. As positive control HUVEC cells treated for 3 h with 5 μM STS were used. **i** Western blot analysis of the autophagy protein LC3. The ratio between LC3-II (14 kDa) and LC3-I (17 kDa) does not change in CD31+ *Flvcr1a* null ECs. **j** Quantification of normalized LC3-II/I ratio. Values are expressed as fold increase. **k** Intracellular heme levels in CD31+ cells isolated from E13.5 embryos. Values for each sample are expressed as the ratio between the fluorescence of CD31+ cells and the total fluorescence (CD31+/-). \**p* \< 0.05. **l** qRT-PCR analysis of *Ho-1* in CD31+ cells from E13.5 control and eKO embryos. Values represent mean ± SEM; *n* = 5. eKO, *Flvcr1a* endothelial knockout; EC endothelial cell; N nucleus; STS Staurosporine

To further characterize the mechanism of cell death promoted by endogenously synthetized heme overload in ECs, we performed electron microscopy on *FLVCR1a*-silenced HMECs both under resting conditions and upon treatment with ALA to stimulate heme synthesis. A proper morphology and organization of the ER and mitochondria was observed in control cells (Fig. [6a](#Fig6){ref-type="fig"}). Conversely, the ER structure in *FLVCR1a*-silenced HMECs appeared disorganized and some swollen ER cisternae were observed (Fig. [6b](#Fig6){ref-type="fig"}). Moreover, a high number of small vacuoles partially containing electron-dense dots were found throughout the cytosol of *FLVCR1a*-silenced HMECs (Fig. [6b](#Fig6){ref-type="fig"}). Importantly, damaged mitochondria characterized by a swollen morphology were also observed in HMECs in the absence of FLVCR1a (Fig. [6b](#Fig6){ref-type="fig"}). Upon ALA treatment, the same morphological alterations appeared also in control cells, which showed a high number of small vacuoles, swollen mitochondria and disorganized ER structure (Fig. [6c](#Fig6){ref-type="fig"}). The phenotype of *FLVCR1a*-silenced HMECs was strongly exacerbated by ALA treatment and huge vacuoles and heavily damaged swollen mitochondria were observed in the cytoplasm (Fig. [6d](#Fig6){ref-type="fig"}). Importantly, these morphological features well resemble paraptotic cell death, similarly to the above described embryonic *Flvcr1a* null ECs. As paraptosis, as well as other PCDs, requires protein synthesis, we studied the effects of the protein synthesis inhibitor cycloheximide (CHX) on heme-induced paraptosis. To this aim, we co-treated control and *FLVCR1a*-deficient HMECs with ALA (5 mM) and CHX (5 μg/ml). Notably, the number and size of intracellular vacuoles was strongly reduced by CHX, indicating that protein synthesis is required for this process (Figs. [6e, f](#Fig6){ref-type="fig"}). Taken together, these data indicate that heme accumulation in human ECs induces a program of death with the morphological features typically observed in paraptotic cells.Fig. 6Intracellular heme accumulation induces cytoplasmic vacuolation in human primary endothelial cells**a-f** Electron microscopy analysis performed on control **a**, **c**, **e** and *FLVCR1a*-silenced **b**, **d**, **f** HMECs. **a** Control HMECs displayed a well-organized ER and normal mitochondria. **b** *FLVCR1a*-deficient HMECs showed some swollen ER cisternae (black arrows) and many vacuoles partially containing electron-dense dots (white arrowheads). Some damaged mitochondria (\*) were also observed. Interestingly, electron-dense deposits (black arrowheads) were found in the cytosol of some FLVCR1a-deficient HMECs. **c** Control HMECs treated with ALA 5 mM for 16 h. ALA treatment induced the same morphological changes observed in the absence of FLVCR1a. Intracellular vacuoles (white arrowheads) and swollen mitochondria (\*), are shown. **d** *FLVCR1a*-silenced HMECs treated with ALA displayed huge intracellular vacuoles (V) and heavily damaged swollen mitochondria (\*), indicating a mechanism of paraptotic cell death. **e**, **f** HMECs co-treated with ALA and CHX (5 μg/ml) for 16 h, are shown. The inhibition of protein synthesis by CHX strongly reduced the number and size of intracellular vacuoles. Electron-dense dots in *FLVCR1a*-silenced cells **f** are indicated by black arrowhead. ER endoplasmic reticulum; G Golgi apparatus; M mitochondrion; N nucleus; V vacuole; CHX Cycloheximide; ALA Aminolevulinic acid

Elevated intracellular ROS have been reported in several models of paraptosis \[[@CR19], [@CR20]\]. As heme is known to promote the formation of ROS, as reported in *FLVCR1a*-silenced human ECs (Figs. [1j, l](#Fig1){ref-type="fig"}), we studied their possible involvement in heme-induced paraptosis. To do this, we directly measured ROS production in ECs isolated from control and *Flvcr1a* eKO embryos. As shown in Supplementary Figure [S4](#MOESM1){ref-type="media"}, we found no differences in generic ROS as well as in mitochondrial superoxide production between control and *Flvcr1a* null CD31+ cells (Supplementary Figures [S4A-B](#MOESM1){ref-type="media"}). Moreover, the expression levels of superoxide dismutase 1 (Sod1) in CD31+ cells did not change between *Flvcr1a* eKO and controls (Supplementary Figure [S4C](#MOESM1){ref-type="media"}). Although we cannot exclude that a mild production of ROS can occur, these data suggest that ROS are rather a contributory cause than a driving force in the induction of heme-triggered endothelial paraptosis *in vivo*.

As proteasome dysfunction and accumulation of unfolded proteins have been described in several paraptotic cells \[[@CR19], [@CR21], [@CR22]\], we investigate the possible involvement of ER stress in heme-induced endothelial paraptosis. To this aim, we evaluated the expression of main ER stress markers in ECs without FLVCR1a. Interestingly, we found a significant induction of *PERK*, *GRP78/BIP* and *GRP94* transcripts in *Flvcr1a* null embryonic ECs, as well as in human ECs silenced for *FLVCR1a* (Figs. [7a-c, e-g](#Fig7){ref-type="fig"}). Another evidence of ER stress derived from the electron micrographs of *Flvcr1a* null ECs, widely characterized by the presence of swollen ER cisternae (Fig. [7d](#Fig7){ref-type="fig"}). Finally, a time-course experiment with the heme precursor ALA on human ECs correlated *de novo* synthetized heme accumulation with increasing expression of GRP78/BIP protein (Figs. [7h, i](#Fig7){ref-type="fig"}). These data strongly indicate that heme-induced paraptosis might be preceded by induction of ER stress.Fig. 7Heme accumulation in ECs induces ER stress**a-c** qRT-PCR analysis of *Perk* (protein kinase R (PKR)-like endoplasmic reticulum kinase) **a**, *Grp78/Bip* (binding immunoglobulin protein) **b** and *Grp94* **c** in CD31+ cells isolated from E13.5 *Flvcr1a* eKO embryos. Data represent mean ± SEM, *n* = 5; \**p* \< 0.05, \*\*\**p* \< 0.001. **d** Electron micrographs from limb transverse section of E13.5 *Flvcr1a* eKO embryo showing the swollen morphology of endoplasmic reticulum (black arrowheads). **e-g** qRT-PCR analysis of *PERK* **e**, *GRP78/BIP* **f** and *GRP94* **g** in *FLVCR1a*-silenced HMECs. Data represent mean ± SEM,*n* = 5; \**p* \< 0.05, \*\**p *\< 0.01. **h** Western blot analysis of GRP78/BIP protein expression in HMECs treated with ALA 5 mM for the indicated times. eKO *Flvcr1a* endothelial knockout; EC endothelial cell; M mitochondrion

Discussion {#Sec7}
==========

In the present study, we show that heme accumulation in ECs due to heme export failure, triggers paraptotic cell death responsible for aberrant angiogenesis (Fig. [8](#Fig8){ref-type="fig"}). These findings might have important implications for physiological, as well as pathological angiogenesis.Fig. 8Schematic representation of FLVCR1a function in endothelial cells.Graphic representation of wild-type **a** and FLVCR1a null **b** endothelial cells. FLVCR1a exports the excess of heme derived from heme biosynthesis, thus contributing to maintain heme homeostasis. The loss of FLVCR1a leads to cytosolic heme accumulation and triggers paraptotic cell death characterized by extensive cytoplasmic vacuolation, swollen morphology of endoplasmic reticulum and large mitochondria without cristae. The effects of FLVCR1a loss in ECs *in vivo* cause deficient angiogenesis, hemorrhages and embryonic lethality. M mitochondrion; ER endoplasmic reticulum; V vacuoles; N nucleus

Heme toxicity on ECs has been widely studied in the context of hemolytic diseases. During hemolysis, hemoglobin derived from lysed erythrocytes, releases free heme that accumulates in plasma and becomes a major source of ROS \[[@CR11], [@CR23]\]. The endothelium is the first tissue facing the heme-related oxidative insult due to intravascular hemolysis. The exposure of the vessel wall to heme leads to ECs activation, which involves increased expression of adhesion molecules, leukocytes recruitment and cytokines production \[[@CR23], [@CR24]\]. In this context, HO1 induction represents a valuable mechanism for counteracting heme toxicity \[[@CR25]\]. Consistently, several articles reported the therapeutic effects of HO1 overexpression in the vascular system \[[@CR26], [@CR27]\]. Here, we show that ECs are also highly sensitive to the accumulation of heme derived by intracellular metabolism. Indeed, heme overload in *FLVCR1a*-deficient ECs is associated with poor cell viability both *in vitro* and *in vivo*. Moreover, in *Flvcr1a*-silenced cells heme overload further increases upon the stimulation of heme biosynthesis. Interestingly, in *Flvcr1a*-deficient ECs, expanded intracellular heme pool triggers a specific compensatory response that is mainly mediated by the inhibition of heme biosynthesis, rather than by the induction of heme catabolism. Thus, heme catabolism (HO1) and export (FLVCR1a) are involved in the management of heme excess derived from extracellular or intracellular sources, respectively. Collectively, these data suggest the existence of distinct heme pools on specific cell compartments, likely accessible to different mechanisms of heme detoxification. This conclusion is supported by data obtained in other cell types and in liver- and intestine-specific *Flvcr1a* null mice, where Ho1 induction cannot reduce heme overload caused by FLVCR1a loss \[[@CR10], [@CR12]\].

*In vivo*, heme overload in *Flvcr1a* null ECs results in increased cell death responsible for disrupted vascularization, extensive hemorrhages and, consequently, embryonic lethality. Reduced viability and defective tubulogenesis demonstrated in *FLVCR1a*-silenced HMECs strongly supports this conclusion.

We identified the mechanism of EC death induced by endogenously synthetized heme accumulation as paraptosis, a specific type of PCD characterized by extensive cytoplasmic vacuolation that begins with a progressive swelling of ER and mitochondria \[[@CR16], [@CR17], [@CR28]\]. The term "paraptosis" was first introduced by Sperandio et al. \[[@CR16]\] to describe a form of PCD morphologically and biochemically distinct from apoptosis. Indeed, paraptosis does not involve the activation of caspases nor the classical morphological changes found in cells undergoing apoptosis \[[@CR16], [@CR17]\]. Similarly to other PCDs, paraptosis is known to require de novo protein synthesis. Consistently, inhibition of protein synthesis by CHX is able to rescue heme-induced cytoplasmic vacuolation in ALA treated *FLVCR1a*-silenced HMECs. The molecular mechanisms through which heme triggers paraptosis in ECs is unclear. ER stress and accumulation of unfolded proteins are known to be involved in paraptosis \[[@CR19], [@CR21], [@CR22], [@CR29], [@CR30]\]. Notably, several indications of ER stress were found in both *Flvcr1a* null embryonic ECs and *FLVCR1a*-silenced human ECs, suggesting that ER stress might contribute to the cell death process. In particular, dilation of the ER-lumen and increased expression of ER stress markers were observed in ECs without FLVCR1a both in vivo and in vitro. Moreover, ALA treatment was shown to increase the expression of GRP78/BIP protein in human ECs, further correlating heme accumulation and ER stress. These data taken together strongly suggest that heme-induced vacuolation can be preceded by induction of ER stress. Consistently, heme excess has been shown to inhibit the proteasome leading to accumulation of misfolded proteins and ER stress \[[@CR31]\]. Furthermore, protein aggregation has been recently reported as a cellular response to oxidative stress induced by heme \[[@CR32]\]. Nevertheless, we cannot exclude a contribution of intracellular ROS to the mechanism of heme-induced EC death. Heme is known to promote the formation of ROS as previously demonstrated in other models of *Flvcr1a* deficiency \[[@CR10], [@CR12]\]. Consistently, *FLVCR1a*-silenced ECs displayed enhanced ROS production. Although we were not able to measure a significant increase of ROS in CD31+ cells from *Flvcr1a* eKO embryos, we think that a mild production of ROS in *Flvcr1a* null ECs might sensitize the cells to paraptosis as previously reported in other systems \[[@CR19]--[@CR21], [@CR33]\]. Finally, the swollen morphology of ER and mitochondria observed in *Flvcr1a* null ECs and *FLVCR1a*-silenced human ECs indicates an imbalance in ions homeostasis (e.g., Ca2+ and K+). Accordingly, alterations in ions exchange between ER and mitochondria are involved in paraptosis \[[@CR21], [@CR34], [@CR35]\].

Interestingly, some natural and synthetic compounds used as anticancer agents, exert a pro-paraptotic effect, which is applied as an alternative way to kill cancer cells resistant to apoptosis \[[@CR29], [@CR30], [@CR36], [@CR37]\]. As evasion of cell death is one of the hallmarks of tumorigenesis, the elucidation of the mechanisms promoting non-canonical types of cell death can provide novel therapeutic options \[[@CR36]\]. In this context, the finding that intracellular heme accumulation promotes paraptosis opens new perspectives based on the manipulation of intracellular heme pool for reducing tumor growth. In particular, angiogenesis is an important rate-limiting step in tumor growth and anti-angiogenesis therapy represents a valuable opportunity for cancer treatment \[[@CR38]\]. Our data suggest that heme-promoted paraptosis might be exploited as a way for reducing tumor angiogenesis. We can speculate that agents aimed at increasing cytosolic heme by promoting heme synthesis, blocking heme export and/or heme catabolism might have anti-angiogenic effects \[[@CR39]\]. These drugs could be used in combination with other drugs to improve antitumor efficacy by killing apoptosis-resistant cells.

Cell death through paraptosis has been reported also in other pathological conditions. For instance, paraptosis has been described in neural development and neurodegeneration (e.g., amyotrophic lateral sclerosis and Huntington's disease), in the ischemic damage and in the context of retina pathophysiology \[[@CR36]\]. Interestingly, *Flvcr1* gene is mutated in posterior column ataxia with retinitis pigmentosa and hereditary sensory and autonomic neuropathy type 2, both characterized by degeneration of specific neuronal cell types \[[@CR14], [@CR40], [@CR41]\]. We hypothesize that impaired FLVCR1 function in these patients might promote paraptosis of specific cell types.

In conclusion, our data unravel the critical role of the physiologic regulation of the intracellular heme pool for the maintenance of ECs homeostasis and their angiogenic functions. We speculate that acting on the endothelial heme pool might provide novel therapeutic options for controlling neo-angiogenesis in cancer and other pathologies characterized by enhanced/aberrant vascularization.

Materials and methods {#Sec8}
=====================

Generation and analysis of Flvcr1a-conditional mutant mice {#Sec9}
----------------------------------------------------------

Endothelial-specific conditional Flvcr1a knockout mice were generated by crossing Flvcr1afl/+; Tie2-Cre male mice with Flvcr1afl/fl female mice \[[@CR10]\] to generate EC-specific deletion of Flvcr1a gene (Flvcr1afl/fl; Tie2-Cre). Upon Cre-mediated recombination, excision of the first exon would fully inactivate the gene in ECs, creating a null Flvcr1a allele (Flvcr1a null). Mice were genotyped by PCR analyses using DNA from yolk sacs or tail biopsies. To detect the Cre allele, primers Cre-Fw (5ʹ-GGACATGTTCAGGGATCGCCAGGCG-3ʹ) and Cre-Rev (5ʹ-GCATAACCAGTGAAACAGCATTGCT-3ʹ) were used. To detect the Flvcr1a null allele, primers ILox-Fw (5ʹ-TCTAAGGCCCAGTAGGACCC-3ʹ) and IILox-Rev (5ʹ-AGAGGGCAACCTCGGTGTCC-3ʹ) were used, given a 320-bp fragment. To analyze the LoxP sites on Flvcr1 gene, primers ILox-Fw (5ʹ-TCTAAGGCCCAGTAGGACCC-3ʹ) and ILox-Rev (5ʹ-GAAAGCATTTCCGTCCGCCC-3ʹ) were used, given a 280-bp band for the floxed allele and a 242-bp band for the wild-type allele (Fig. [2a](#Fig2){ref-type="fig"}). Embryos were obtained from timed pregnant females with the morning of vaginal plug considered E0.5. All experiments were approved by the animal studies committee of the University of Torino (Italy).

Whole-mount immunostaining {#Sec10}
--------------------------

Whole-mount staining was performed as previously described \[[@CR42]\], using anti-mouse CD31 (Pecam-1) monoclonal antibody (BD Biosciences, Franklin Lakes, NJ, USA). 3,3′-diaminobenzidine (DAB)/hydrogen peroxide was used for visualization.

CD31+ cells isolation from mouse embryo {#Sec11}
---------------------------------------

E13.5--14.5 embryos were isolated from Tie2-Cre transgenic mice and minced into 1--2 mm fragments with a scalpel. After rinsing in phosphate-buffered saline (PBS), the tissue pieces were incubated for 45 min at 37 °C in 10 ml of pre-warmed PBS with collagenase (5 mg/ml, Collagenase Type II, Worthington, CLS-2) with shaking until a single-cell suspension was obtained. During this incubation, the cells were dissociated at 10-min intervals by pipetting. To stop the collagenase activity, Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine serum (FBS; Invitrogen) was added to the cell suspension, gently pelleted and rinsed with PBS. The cells in PBS were then filtered through a cell strainer (40 mm mesh, BD Falcon). After centrifugation, cells were re-suspended in 1 ml NH~4~Cl 154 mM, overlaid onto 5 ml of FBS and centrifuged. If red blood cells were not fully removed, this step was repeated. Cells were washed and re-suspended in PBS. Then, embryonic cells were magnetically labeled with MicroBeads conjugated to monoclonal anti‑mouse CD31 antibody (Miltenyi Biotec) and loaded onto a MACS® Column, which was placed in the magnetic field of a MACS Separator. After removing the column from the magnetic field, the magnetically retained CD31+ cells were eluted as the positively selected cell fraction.

RNA extraction and real-time PCR analysis {#Sec12}
-----------------------------------------

Total RNA was extracted from tissue and cell samples using PureLink® RNA Mini Kit (ThermoFisher Scientific). For quantitative real-time polymerase chain reaction (qRT-PCR), 0.5--1 μg total RNA was transcribed into complementary DNA by M-MLV reverse transcriptase (Invitrogen) and random primers (Invitrogen). qRT-PCR was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Monza, Italy). Primers and probes were designed using the Universal ProbeLibrary Assay Design Center software (www. lifescience.roche.com). For *FLVCR1a*, specific primers and the probe were designed using Primer Express Software Version 3.0 (Applied Biosystems). Transcript abundance, normalized to 18s mRNA expression (for mouse tissues) or to beta-actin mRNA expression (for human cells), is expressed as a fold increase over a calibrator sample.

Western blotting {#Sec13}
----------------

For western blot analysis, 20 μg of CD31+ cells protein extracts were loaded on 15% sodium dodecyl sulfate-polyacrylamide gels and analyzed by western blotting as previously described \[[@CR43]\]. Cleaved caspase-3 (Asp175) antibody (Cell Signaling) was used to recognize the activated caspase-3 resulting from cleavage adjacent to Asp175 (17--19 kDa). Full-length caspase-3 (Cell Signaling) antibody was used to detect the full-length protein (35 kDa). Rabbit polyclonal antibody against LC3 (TA301542, Origene) was used to detect conversion of LC3-I (cytosolic) to LC3-II (autophagic vacuole membrane bound). Purified mouse anti-Grp78/Bip (610979, BD Transduction Laboratories) was used to detect the protein expression in HMECs.

Cell culture {#Sec14}
------------

HUVECs were propagated in M199 medium (Invitrogen) with 20% FBS (Invitrogen), 100 U/ml penicillin, 100 μg/ml streptomycin, 20 U/ml Heparin sodium salt from porcine intestinal mucosa (Sigma), 10 ng/ml recombinant human Fibroblast Growth Factor (FGF)-basic (PeproTech). HUVECs were used up to passages 6. Human adult dermal microvascular ECs were purchased by Lonza and propagated in EndoGRO MV-VEGF medium (Millipore, Merck, Italy) and used up to passages 12. Cells were maintained at 37 °C under a 5% CO~2~ atmosphere. To induce endogenous heme biosynthesis, 5-aminolevulinic acid hydrochloride (A3785, Sigma) was added to the cell medium. To inhibit protein synthesis, CHX (5 μg/ml, Sigma) was added to the cell medium.

*FLVCR1a* silencing {#Sec15}
-------------------

A set of five pLKO.1 HIV-based lentiviral vectors targeting human *FLVCR1* gene were purchased (RHS4533-NM_014053, Dharmacon). A shRNA against the first exon of human *FLVCR1* gene was used to specifically downregulate *FLVCR1a* expression. The lentiviruses pLKO.1-scr (expressing a "scramble" shRNA as control) and pLKO.1-1a (expressing the shRNA specific for *FLVCR1a*) were produced in HEK293FT cells. HMEC and HUVEC cells were infected with the lentiviruses in the presence of Sequa-brene. Following lentiviral infection, cells were selected with 0.02 μg/ml puromycin.

Measurement of heme concentration {#Sec16}
---------------------------------

Intracellular heme concentration was measured using a fluorescence assay, as previously reported \[[@CR44]\]. Briefly, HMEC and HUVEC cells or CD31+/- embryonic cells were collected and 2 M oxalic acid was added to them. Samples were heated at 95 °C for 30 min leading to iron removal from heme. Fluorescence (wavelengths: excitation 400 nm -- emission 662 nm) of the resultant protoporphyrin was assessed on a Glomax Multi Detection System (Promega Corporation). The endogenous protoporphyrin content (measured in parallel unheated samples in oxalic acid) was subtracted. Data were normalized to total protein concentration in each sample.

Measurement of intracellular ROS content in vitro {#Sec17}
-------------------------------------------------

Accumulation of ROS in HMEC and HUVEC cells was assessed using the oxidant-sensitive fluorescent dye 29,79-dichlorodihydrofluoroscein diacetate (H2DCFDA, ThermoFisher Scientific). Cells were incubated with 5 mM H2DCFDA in cell medium for 30 min at 37 °C under 5% CO~2~ atmosphere. Then, cells were washed twice with PBS and lysed in TBS 1 × 1% Triton. A quantity of lysate correspondent to 10 μg protein was analyzed. Fluorescence was recorded at excitation and emission wavelengths of 485 and 530, respectively, on a Glomax Multi Detection System (Promega Corporation). Background fluorescence of cells untreated with H2DCFDA was subtracted from the total fluorescence. Results are expressed as arbitrary fluorescence unit.

MTT assay and Annexin V affinity assay {#Sec18}
--------------------------------------

In all, 5×103 HMEC or HUVEC cells were plated on 96 multiwells, and every 24 h cell growth was evaluated by MTT assay (Roche) according to the manufacturer's instructions. For Annexin V affinity assay, 5×105 cells were collected, washed in PBS and labeled with Annexin V (BD Biosciences) for 20 min. Then, 2 μl of propidium iodide (1 mg/ml) (Sigma-Aldrich) were added. Annexin V emission was detected in the green channel (525 nm) and propidium iodide in the red channel (575 nm) on a FACSCalibur (BD Biosciences) using Cell Quest Pro Software (BD Biosciences).

Tubulogenesis assay {#Sec19}
-------------------

In vitro formation of capillary-like structures was studied on growth factor-reduced Matrigel (BD Biosciences) in 24-well plates. Cells (3.5 × 10^4^\] cells per well) were seeded onto Matrigel-coating in EndoGRO MV-VEGF (Millipore). Cell organization onto Matrigel was observed with a Nikon Eclipse Ti E microscope using a Nikon Plan 10X/0,10 objective and cells were kept at 37 °C and 5% CO~2~ during the experiment. Images were acquired after 8 h. At least three independent experiments were done for each experimental condition. ImageJ's Angiogenesis Analyzer was used to analyze: master segments, master junctions, isolated segments, total length, total master segments length and nodes.

Micro-computed tomography {#Sec20}
-------------------------

Micro-CT analysis was performed on E13.5 mouse embryos using a Bruker Skyscan 1172 micro-CT. Embryos were fixed in formalin and then stained for 6 days with a soft tissue contrast agent (phosphotungstic acid 2.5% dissolved in water). Acquisition were performed at 80 kV using a 0.5 mm Al filter at a resolution of 3 µm, 0.4° of rotation step, 360° scan, 4× frame averaging.

Electron microscopy {#Sec21}
-------------------

The transmission electron micrographs were obtained at the Advanced Light and Electron Microscopy BioImaging Center (ALEMBIC), San Raffaele, Milano, Italy.

Statistics {#Sec22}
----------

Results were expressed as mean ± SEM. Statistical analyses were performed using one-way or two-way analysis of variance or Student's *t*-test. A *p*-value of \<0.05 was considered significant.
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